Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 1620

Prof Max Topp - University of Würzburg, Würzburg, Germany

Prof Max Topp talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a first in-human phase I dose escalation study using the bispecific antibody construct, AMG 420 in patients with relapsed/refractory multiple myeloma.

He explains the use of AMG 420, along with the primary objectives, safety and tolerability of the drug. Secondary endpoints included anti-tumour probabilities of this therapy.

Prof Topp reports that the maximum tolerated dose was reached (800 mg/day) along with the safety and efficacy profile of this treatment.

In the upcoming phase II trial, Prof Topp hopes to consolidate the positive results achieved in this study and believes that AMG 420 may have a potential role in treating MRD-positive myeloma after front-line therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation